iSpecimen Selected by U.S. Government and Private Researchers to Supply Critical Human Biospecimens for Advanced Phase of COVID-19 Research. ISPC is expected to have great upside potential, in my opinion.

These are some investor highlights:

4 ~200 Healthcare Provider / Supplier Organizations ~400 Customer Organizations

1. Early-stage opportunity with a first mover advantage

2. $3B-$4B global biospecimen market growing at 10-15% per year1

3. Unique two-sided marketplace disrupting the biospecimen procurement process 4. 90% year-over-year revenue growth (FY 2020 vs. FY 2019) and 57% year-over-y$iSpecimen Inc.(ISPC)$